Eli Lilly's olomorasib shows clinical promise in first-line NSCLC treatment, potentially bolstering the company's oncology pipeline following positive ESMO data.
Eli Lilly's presentation at the ESMO congress demonstrated that olomorasib, when combined with standard-of-care immunotherapy and chemotherapy, shows significant efficacy in treating first-line advanced KRAS G12C-mutant NSCLC. This clinical progress reinforces the company's oncology pipeline, positioning it to address a critical unmet need in lung cancer treatment across various PD-L1 expression levels.
Olomorasib is being studied for the treatment of first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC).
The study evaluated olomorasib in combination with standard-of-care immunotherapy, with or without chemotherapy.
Eli Lilly announced promising clinical data for olomorasib, a KRAS G12C inhibitor, in treating first-line advanced non-small cell lung cancer. The results, presented at the ESMO congress, demonstrate efficacy when combined with standard-of-care immunotherapy and chemotherapy across various PD-L1 expression levels.
The data strengthens Eli Lilly's oncology pipeline by validating the potential of olomorasib as a first-line treatment option for patients with KRAS G12C-mutant non-small cell lung cancer.